Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences reports positive progression in the second stage of GaRP-IBS trial for Irritable Bowel Syndrome, with recruitment extended into Q3 CY2024 and results expected by the year’s end. The company has seen over 1,000 expressions of interest, with 18 participants already enrolled and 20 in screening, supported by a successful A$1.0m capital raise. The trial, which follows a successful Phase II Stage 1, is on budget and aims to confirm promising interim results.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
